1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT

 
• By Alaric DeArment

Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.

• Source: Shutterstock

Deciphera Pharmaceuticals, Inc.’s Phase III vimseltinib has a potentially smooth path to market in tenosynovial giant cell tumor (TGCT) thanks to a safety profile more benign than a competing drug for the condition already on the market. Decipher should also benefit from marketing to physicians that mostly overlaps with the one that Deciphera targets for its drug for gastrointestinal stromal tumors (GIST).

The Waltham, MA-based company announced 30 October positive topline results from the Phase III MOTION study of vimseltinib as well as updated Phase I/II results from a study of the drug in the same indication. MOTION met its primary endpoint of objective response rate (ORR) and all key secondary endpoints at week 25 compared with placebo

Key Takeaways

  • Vimseltinib showed a positive improvement in objective response rate compared with placebo in the Phase III MOTION trial, but no cholestatic hepatotoxicity.

  • The lack of the potentially fatal liver toxicity, plus Deciphera’s existing commercial infrastructure for Qinlock, could give vimseltinib a significant market advantage

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.